Israel's MediWound Q1 revenue misses analyst expectations
Israel's MediWound Q1 revenue misses analyst expectations
Overview
Israel biotechnology firm's Q1 revenue declined and missed analyst expectations
Company reaffirmed full-year 2026 revenue guidance of $24-26 mln
Q1 revenue decline driven by BARDA timing and postponed shipments due to regional conflict
Outlook
MediWound reaffirms 2026 full-year revenue guidance at $24-26 mln
Company expects EscharEx Phase III trial enrollment completion by end of Q1 2027
Initial NexoBrid BARDA procurement activity expected to begin in H2 2026
Result Drivers
BARDA REVENUE TIMING - Co said Q1 revenue decline was primarily due to timing of BARDA-related revenues
POSTPONED SHIPMENTS - Co cited postponed shipments related to regional conflict as a factor in lower Q1 revenue
HIGHER R&D SPENDING - Research and development expenses increased due to costs associated with the EscharEx VALUE Phase III trial
Company press release: ID:nGNX2dV09w
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Miss | $1.5 mln | $3.12 mln (6 Analysts) |
Q1 EPS |
| -$0.23 |
|
Q1 Net Income |
| -$3 mln |
|
Q1 Adjusted EBITDA | Beat | -$7 mln | -$7.81 mln (2 Analysts) |
Q1 Gross Profit |
| $323,000 |
|
Q1 Operating Income |
| -$8 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Mediwound Ltd is $31.50, about 88.8% above its May 26 closing price of $16.68
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)